HC Wainwright reiterated their buy rating on shares of Redhill Biopharma Ltd. (NASDAQ:RDHL) in a report issued on Tuesday morning. The brokerage currently has a $36.00 target price on the biotechnology company’s stock.
RDHL has been the topic of a number of other research reports. Zacks Investment Research raised Redhill Biopharma from a sell rating to a hold rating in a research report on Tuesday, August 29th. UBS AG initiated coverage on Redhill Biopharma in a research report on Wednesday, September 13th. They set a reduce rating on the stock. Roth Capital dropped their price target on Redhill Biopharma from $27.00 to $20.00 and set a buy rating on the stock in a research report on Tuesday, November 14th. Finally, Seaport Global Securities initiated coverage on Redhill Biopharma in a research report on Friday, October 6th. They set a buy rating and a $19.00 price target on the stock. One analyst has rated the stock with a sell rating, one has given a hold rating and four have issued a buy rating to the stock. Redhill Biopharma presently has a consensus rating of Buy and a consensus target price of $21.10.
Redhill Biopharma (NASDAQ:RDHL) opened at $5.02 on Tuesday. Redhill Biopharma has a 1 year low of $4.82 and a 1 year high of $12.09.
ILLEGAL ACTIVITY WARNING: “Redhill Biopharma Ltd. (RDHL) Stock Rating Reaffirmed by HC Wainwright” was first published by Chaffey Breeze and is the sole property of of Chaffey Breeze. If you are reading this piece on another website, it was illegally stolen and reposted in violation of US & international copyright & trademark laws. The correct version of this piece can be read at https://www.chaffeybreeze.com/2017/11/25/redhill-biopharma-ltd-rdhl-stock-rating-reaffirmed-by-hc-wainwright.html.
About Redhill Biopharma
Redhill Biopharma Ltd, is an Israel-based specialty biopharmaceutical company. The Company focuses on the development and commercialization of late clinical-stage, proprietary, orally-administered, small molecule drugs for the treatment of gastrointestinal and inflammatory diseases and cancer. It offers the following gastrointestinal products in the United States: Donnatal, a prescription oral adjunctive drug used in the treatment of Irritable Bowel Syndrome (IBS) and acute enterocolitis, as well as EnteraGam, a medical food intended for the dietary management, under medical supervision, of chronic diarrhea and loose stools.
Receive News & Ratings for Redhill Biopharma Ltd. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Redhill Biopharma Ltd. and related companies with MarketBeat.com's FREE daily email newsletter.